RF
ASND icon

Roxbury Financial’s Ascendis Pharma A/S ASND Stock Holding History

Roxbury Financial’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-42
Closed -$9.61K – 412
2026
Q1 		$9.61K Hold
42
– – 0.01% 304
2025
Q4 		$8.96K Hold
42
– – 0.01% 302
2025
Q3 		$8.35K Hold
42
– – 0.01% 296
2025
Q2 		$7.25K Buy
42
+32
+320% +$5.21K 0.01% 297
2025
Q1 		$1.57K Buy
+10
New +$1.43K ﹤0.01% 328

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Roxbury Financial's ASND Position: Q2 2026 in Review

Roxbury Financial sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 42 shares — an estimated $9.61K sold.

Roxbury Financial first reported a position in ASND in Q1 2025 and held it in 5 quarters. The position peaked at $9.61K in Q1 2026. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

  • Roxbury Financial reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
  • Roxbury Financial sold 42 Ascendis Pharma A/S shares in Q2 2026, an estimated $9.61K.
  • Roxbury Financial first reported a position in Ascendis Pharma A/S in Q1 2025 and held it in 5 quarters.
  • Roxbury Financial's Ascendis Pharma A/S position peaked at $9.61K in Q1 2026.
  • 312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Roxbury Financial's 13F filing for Q2 2026, filed 1 Jul 2026.